Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants
- 16 November 2024
- journal article
- research article
- Published by Elsevier in Journal of Virological Methods
- Vol. 332, 115073
Abstract
No abstract availableKeywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysisThe Lancet Microbe, 2024
- Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysisNature Communications, 2023
- A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategyVaccine, 2023
- WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific communityThe Lancet Microbe, 2022
- The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitroVirologica Sinica, 2022
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA DisplayACS Central Science, 2021
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patientsCell, 2021
- Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease OutbreaksStem Cell Reports, 2021
- Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale productionThe Journal of Gene Medicine, 2005